MIA
RVNC

Milestone Investment Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Milestone Investment Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-175
Closed -$2.01K – 443
2023
Q3 		$2.01K Buy
+175
New +$3.37K ﹤0.01% 375
2023
Q2 		– Sell
-175
Closed -$5.64K – 439
2023
Q1 		$5.64K Buy
+175
New +$5.46K ﹤0.01% 324

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Milestone Investment Advisors's RVNC Position: Q4 2023 in Review

Milestone Investment Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 175 shares — an estimated $2.01K sold.

Milestone Investment Advisors first reported a position in RVNC in Q1 2023 and held it in 2 quarters. The position peaked at $5.64K in Q1 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Milestone Investment Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Milestone Investment Advisors sold 175 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $2.01K.
  • Milestone Investment Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 2 quarters.
  • Milestone Investment Advisors's Revance Therapeutics, Inc. position peaked at $5.64K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Milestone Investment Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.